Amgen's biosimilar version of Roche’s top selling cancer drug, Avastin has been approved in the US, making it the first ever cancer biosimilar approved by the FDA.
Novartis' breast cancer treatment Kisqali has gained final EU approval today - and the company is confident it can follow this with a swift reimbursement recommendation from the UK's NICE.<
